title: A pharmacokinetic study of GC-1 delivery using a nanochannel membrane device.
abstract: This study demonstrated a nanochannel membrane device (NMD) for controlled and sustained release of GC-1 in rats, in the context of the treatment of metabolic syndrome. Release profiles were established in vitro both with and without 5% labrasol for over 2 months. In vivo pharmacokinetic evaluation showed effective GC-1 plasma concentrations, which resulted in significant reductions in body weight after just one week of treatment when compared to the NMD releasing vehicle only (PBS). We also provided evidence that rats treated with NMD-GC-1 present sub-active thyroids and clear differences in the morphology of the epithelium and follicles as compared to the controls, while the heart showed changes in weight. Moreover, body temperatures remained stable throughout treatment, and glucose, pancreatic islet size, and liver histology appeared similar between the treated and control groups. Prolonged constant administration of GC-1 from the NMD proved to be a valid strategy to facilitate weight loss.
authors.affiliation: Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA.
authors.forename: Carly S
authors.initials: CS
authors.lastname: Filgueira
authors.affiliation: Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA; Department of Oncology and Onco-Hematology, University of Milan, Milan, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Ballerini
authors.affiliation: Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA.
authors.forename: Eugenia
authors.initials: E
authors.lastname: Nicolov
authors.affiliation: Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA.
authors.forename: Corrine Ying Xuan
authors.initials: CYX
authors.lastname: Chua
authors.affiliation: Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA.
authors.forename: Priya
authors.initials: P
authors.lastname: Jain
authors.affiliation: Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA.
authors.forename: Zachary W
authors.initials: ZW
authors.lastname: Smith
authors.affiliation: Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA.
authors.forename: April L
authors.initials: AL
authors.lastname: Gilbert
authors.affiliation: Department of Oncology and Onco-Hematology, University of Milan, Milan, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Scaglione
authors.affiliation: Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA. Electronic address: agrattoni@houstonmethodist.org.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Grattoni
mesh_terms: D000085:Acetates / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000818:Animals; D001835:Body Weight; D008099:Liver; D036103:Nanotechnology; D010636:Phenols / Q000008:administration & dosage / Q000493:pharmacokinetics*; D051381:Rats; D011916:Rats, Inbred F344
chemical_list: D000085:Acetates; C413355:GC 1 compound; D010636:Phenols
keywords: GC-1 (Sobetirome); Nanochannel membrane device (NMD); Pharmacokinetic; Sobetirome (PubChem CID: 9862248); Thyroid gland; Weight loss